Moderna's mFLUSIVA Approved for 50+, Ebola Vaccine Trial Launched
MRNA has more than doubled off its 52-week low of $22.28.
Summary
The FDA approved Moderna's mFLUSIVA flu vaccine for adults 50+, with Phase 3 data showing 26.6% higher efficacy versus standard vaccines. This follows the initial approval report on August 6, but adds new details: limited U.S. supply for the 2026–27 season and a Phase 1 trial launch for a Bundibugyo Ebola vaccine, with plans for 500,000 affordable doses for low- and middle-income countries. Shares moved on both the flu vaccine progress and the Ebola trial, with an after-hours rally of about 1.5% tied to vaccine policy talks. The Ebola program expands Moderna's infectious disease pipeline beyond its core respiratory franchise, potentially opening a new revenue stream. The limited flu vaccine supply could constrain near-term sales but underscores strong demand. Watch for updates on the Ebola trial's progress and any policy developments that could affect vaccine distribution.
At the time of this announcement, MRNA was trading at $60.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.6B. The 52-week trading range was $22.28 to $85.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.